Atara Biotherapeutics (ATRA)
(Delayed Data from NSDQ)
$11.55 USD
+0.03 (0.26%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $11.35 -0.20 (-1.73%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Fundamental Charts
About Market Cap
As of the previous market close, Atara Biotherapeutics, Inc. has a market cap of $68.68M, which represents its share price of $11.52 multiplied by its outstanding shares number of 5.96M. As a small-cap company, ATRA's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
ATRA 11.55 +0.03(0.26%)
Will ATRA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ATRA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATRA
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates
CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates
ATRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Abbott's Q1 Earnings Coming Up, Medical Devices Arm in Focus
Atara Biotherapeutics (ATRA) Moves to Buy: Rationale Behind the Upgrade
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates
Other News for ATRA
Atara Biotherapeutics (ATRA) Shares Surge After Priority Review Grant
Atara gets FDA priority review for Tabelecleucel application
Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics ...
FDA Accepts Atara Biotherapeutics' BLA for Tabelecleucel (ATRA) | ATRA Stock News
Atara Biotherapeutics announces FDA acceptance of tabelecleucel BLA